Bacteremia due to Moraxella osloensis: a case report and literature review. 2018

Yuta Maruyama, and Tomonari Shigemura, and Koki Aoyama, and Noriyuki Nagano, and Yozo Nakazawa
Shinshu Ueda Medical Center, Department of Pediatrics, Ueda, Japan.

Herein we report the case of a 10-year-old boy with an autosomal mosaic mutation who developed bacteremia. The causative agent was identified as Moraxella osloensis by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry and 16S rRNA gene sequencing. In the pediatric population, there have been 13 case reports of infection attributed to M. osloensis and this is the fifth reported case of pediatric bacteremia due to M. osloensis. After Moraxella species infection was confirmed, the patient recovered with appropriate antimicrobial therapy. It is important to consider that M. osloensis can cause serious infections, such as bacteremia, in otherwise healthy children.

UI MeSH Term Description Entries
D008297 Male Males
D009016 Moraxella A genus of gram-negative, aerobic bacteria occurring as rods (subgenus Moraxella) or cocci (subgenus Branhamella). Its organisms are parasitic on the mucous membranes of humans and other warm-blooded animals.
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000900 Anti-Bacterial Agents Substances that inhibit the growth or reproduction of BACTERIA. Anti-Bacterial Agent,Anti-Bacterial Compound,Anti-Mycobacterial Agent,Antibacterial Agent,Antibiotics,Antimycobacterial Agent,Bacteriocidal Agent,Bacteriocide,Anti-Bacterial Compounds,Anti-Mycobacterial Agents,Antibacterial Agents,Antibiotic,Antimycobacterial Agents,Bacteriocidal Agents,Bacteriocides,Agent, Anti-Bacterial,Agent, Anti-Mycobacterial,Agent, Antibacterial,Agent, Antimycobacterial,Agent, Bacteriocidal,Agents, Anti-Bacterial,Agents, Anti-Mycobacterial,Agents, Antibacterial,Agents, Antimycobacterial,Agents, Bacteriocidal,Anti Bacterial Agent,Anti Bacterial Agents,Anti Bacterial Compound,Anti Bacterial Compounds,Anti Mycobacterial Agent,Anti Mycobacterial Agents,Compound, Anti-Bacterial,Compounds, Anti-Bacterial
D016133 Polymerase Chain Reaction In vitro method for producing large amounts of specific DNA or RNA fragments of defined length and sequence from small amounts of short oligonucleotide flanking sequences (primers). The essential steps include thermal denaturation of the double-stranded target molecules, annealing of the primers to their complementary sequences, and extension of the annealed primers by enzymatic synthesis with DNA polymerase. The reaction is efficient, specific, and extremely sensitive. Uses for the reaction include disease diagnosis, detection of difficult-to-isolate pathogens, mutation analysis, genetic testing, DNA sequencing, and analyzing evolutionary relationships. Anchored PCR,Inverse PCR,Nested PCR,PCR,Anchored Polymerase Chain Reaction,Inverse Polymerase Chain Reaction,Nested Polymerase Chain Reaction,PCR, Anchored,PCR, Inverse,PCR, Nested,Polymerase Chain Reactions,Reaction, Polymerase Chain,Reactions, Polymerase Chain
D016470 Bacteremia The presence of viable bacteria circulating in the blood. Fever, chills, tachycardia, and tachypnea are common acute manifestations of bacteremia. The majority of cases are seen in already hospitalized patients, most of whom have underlying diseases or procedures which render their bloodstreams susceptible to invasion. Bacteremias
D016896 Treatment Outcome Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series. Rehabilitation Outcome,Treatment Effectiveness,Clinical Effectiveness,Clinical Efficacy,Patient-Relevant Outcome,Treatment Efficacy,Effectiveness, Clinical,Effectiveness, Treatment,Efficacy, Clinical,Efficacy, Treatment,Outcome, Patient-Relevant,Outcome, Rehabilitation,Outcome, Treatment,Outcomes, Patient-Relevant,Patient Relevant Outcome,Patient-Relevant Outcomes
D045828 Moraxellaceae Infections Infections with bacteria of the family MORAXELLACEAE. Moraxella Infections,Psychobacter Infections,Infection, Moraxella,Infection, Moraxellaceae,Infection, Psychobacter,Infections, Moraxella,Infections, Moraxellaceae,Infections, Psychobacter,Moraxella Infection,Moraxellaceae Infection,Psychobacter Infection
D019032 Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization A mass spectrometric technique that is used for the analysis of large biomolecules. Analyte molecules are embedded in an excess matrix of small organic molecules that show a high resonant absorption at the laser wavelength used. The matrix absorbs the laser energy, thus inducing a soft disintegration of the sample-matrix mixture into free (gas phase) matrix and analyte molecules and molecular ions. In general, only molecular ions of the analyte molecules are produced, and almost no fragmentation occurs. This makes the method well suited for molecular weight determinations and mixture analysis. Laser Desorption-Ionization Mass Spectrometry, Matrix-Assisted,MALD-MS,MALDI,Mass Spectrometry, Matrix-Assisted Laser Desorption-Ionization,Mass Spectroscopy, Matrix-Assisted Laser Desorption-Ionization,Matrix-Assisted Laser Desorption-Ionization Mass Spectrometry,Spectroscopy, Mass, Matrix-Assisted Laser Desorption-Ionization,MALDI-MS,MS-MALD,SELDI-TOF-MS,Surface Enhanced Laser Desorption Ionization Mass Spectrometry,Laser Desorption Ionization Mass Spectrometry, Matrix Assisted,MALDI MS,Mass Spectrometry, Matrix Assisted Laser Desorption Ionization,Mass Spectroscopy, Matrix Assisted Laser Desorption Ionization,Matrix Assisted Laser Desorption Ionization Mass Spectrometry

Related Publications

Yuta Maruyama, and Tomonari Shigemura, and Koki Aoyama, and Noriyuki Nagano, and Yozo Nakazawa
December 2019, Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy,
Yuta Maruyama, and Tomonari Shigemura, and Koki Aoyama, and Noriyuki Nagano, and Yozo Nakazawa
January 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America,
Yuta Maruyama, and Tomonari Shigemura, and Koki Aoyama, and Noriyuki Nagano, and Yozo Nakazawa
January 2015, Japanese journal of infectious diseases,
Yuta Maruyama, and Tomonari Shigemura, and Koki Aoyama, and Noriyuki Nagano, and Yozo Nakazawa
January 2001, Scandinavian journal of infectious diseases,
Yuta Maruyama, and Tomonari Shigemura, and Koki Aoyama, and Noriyuki Nagano, and Yozo Nakazawa
June 2016, Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia,
Yuta Maruyama, and Tomonari Shigemura, and Koki Aoyama, and Noriyuki Nagano, and Yozo Nakazawa
January 2021, Clinical laboratory,
Yuta Maruyama, and Tomonari Shigemura, and Koki Aoyama, and Noriyuki Nagano, and Yozo Nakazawa
February 2014, Anales de pediatria (Barcelona, Spain : 2003),
Yuta Maruyama, and Tomonari Shigemura, and Koki Aoyama, and Noriyuki Nagano, and Yozo Nakazawa
June 1990, Archives of internal medicine,
Yuta Maruyama, and Tomonari Shigemura, and Koki Aoyama, and Noriyuki Nagano, and Yozo Nakazawa
July 1969, The Journal of pediatrics,
Yuta Maruyama, and Tomonari Shigemura, and Koki Aoyama, and Noriyuki Nagano, and Yozo Nakazawa
October 2008, Transplant international : official journal of the European Society for Organ Transplantation,
Copied contents to your clipboard!